Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Wiliam Blair Issues Note Regarding New Guidelines On A ImmunoGen Drug, The National Comprehensive Cancer Network Just Released New Guideline Which Include Elahere, As A Preferred Regimen

By Benzinga Newsdesk
Today, 5:04 AM
The National Comprehensive Cancer Network (NCCN) just released new guidelines (Version 1.2023) for the treatment of ovarian cancer, which include Elahere (IMGN drug) as a preferred regimen.  This comes as a particular surprise to the upside, since it occurred faster than our (and likely the Street’s) expectations. It is our view that

IMGN

Read More
4 minute read

Mirati Plays Catch-Up With Amgen, Gilead’s 2nd Try With AIDS Drug, Cytokinetics’ Adcom Test And More: Key Nov FDA Decisions For Biotech Investors

By Shanthi Rexaline
Today, 5:04 AM
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

AMGN